# Phase 2 rectal cancer trials recruiting: 102 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 102 trials in phase 2 for rectal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 rectal cancer trials: 102 rows for $5.10, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/rectal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 102
- Recruiting or not yet: 102
- Read on: November 19, 2026

## Trials

The 25 newest of 102, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07888309 | SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer | Ruijin Hospital | Phase 2 | Recruiting | Rectal Neoplasms, Rectal Cancer, Adenocarcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888309) |
| September 29, 2026 | NCT07847229 | A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Rectal Cancer, Radiotherapy, Immunotherapy, Chemotherapy | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847229) |
| September 22, 2026 | NCT07833319 | Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer | Peking University Cancer Hospital & Institute | Phase 2 | Recruiting | Rectal Cancers | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833319) |
| September 14, 2026 | NCT07817888 | mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 | Not yet recruiting | Phase 2 Study | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817888) |
| September 9, 2026 | NCT07810114 | Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally... | Fudan University | Phase 2 | Not yet recruiting | Rectal Cancer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810114) |
| August 21, 2026 | NCT07779694 | 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer | Zhejiang University | Phase 2 | Not yet recruiting | pMMR/MSS, Locally Advanced Rectal Carcinoma, Fasting, Intermittent | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779694) |
| August 19, 2026 | NCT07774754 | Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Rectal Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774754) |
| August 14, 2026 | NCT07765667 | NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 | Not yet recruiting | Rectal Adenocarcinoma, High-Risk Cancer, MSS | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765667) |
| July 30, 2026 | NCT07735624 | RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735624) |
| July 9, 2026 | NCT07691489 | A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Not yet recruiting | Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691489) |
| June 25, 2026 | NCT07669220 | A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX... | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 | Recruiting | Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy, FOLFOX | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669220) |
| June 15, 2026 | NCT07646639 | Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Rectal Cancer, Radiotherapy | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646639) |
| June 3, 2026 | NCT07622771 | Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized... | Sun Yat-sen University | Phase 2 | Recruiting | Rectal Cancers | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622771) |
| June 2, 2026 | NCT07622017 | KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 | Recruiting | Rectal Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622017) |
| May 19, 2026 | NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 | City of Hope Medical Center | Phase 2 | Recruiting | Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IIB Colon... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595874) |
| May 19, 2026 | NCT07594925 | Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Rectal Cancer | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594925) |
| May 12, 2026 | NCT07580339 | Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Not yet recruiting | Rectal Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07580339) |
| April 23, 2026 | NCT07548736 | Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 | Not yet recruiting | Acute Radiation Enteritis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07548736) |
| April 22, 2026 | NCT07543848 | A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course... | Chongqing University Cancer Hospital | Phase 2 | Not yet recruiting | Rectal Neoplasms, Rectal Adenocarcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543848) |
| April 14, 2026 | NCT07527520 | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced... | Fudan University | Phase 2 | Not yet recruiting | Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab, pMMR/MSS | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527520) |
| April 7, 2026 | NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 | Not yet recruiting | Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer, Rectal Cancers | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516210) |
| April 3, 2026 | NCT07509424 | Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Rectal Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509424) |
| March 9, 2026 | NCT07458529 | Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer | Seventh Medical Center of PLA General Hospital | Phase 2 | Recruiting | Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9, Tislelizumab, Randomized | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458529) |
| February 25, 2026 | NCT07433673 | Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) | Columbia University | Phase 2 | Recruiting | Colon and Rectal Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07433673) |
| February 12, 2026 | NCT07407647 | Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer | Ohio State University Comprehensive Cancer Center | Phase 2 | Recruiting | Anal Carcinoma, Cervical Carcinoma, Malignant Female Reproductive System Neoplasm, Rectal Carcinoma, Vaginal Carcinoma... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407647) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sixth Affiliated Hospital, Sun Yat-sen University | 8 |
| Sun Yat-sen University | 7 |
| Fudan University | 7 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Sir Run Run Shaw Hospital | 3 |
| Ruijin Hospital | 3 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Zhejiang University | 2 |
| City of Hope Medical Center | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| Shanghai Zhongshan Hospital | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| University of Nebraska | 1 |
| University Hospital, Geneva | 1 |
| M.D. Anderson Cancer Center | 1 |
| Peking Union Medical College Hospital | 1 |
| AC Camargo Cancer Center | 1 |
| First Affiliated Hospital of Guangxi Medical University | 1 |
| Affiliated Cancer Hospital of Shantou University Medical College | 1 |
| Ain Shams University | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Shandong Provincial Hospital | 1 |
| Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Chongqing University Cancer Hospital | 1 |
| University Hospital Tuebingen | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 52 |
| United States | 21 |
| Germany | 5 |
| Italy | 3 |
| Egypt | 2 |
| France | 2 |
| Spain | 2 |
| Taiwan | 2 |
| Switzerland | 1 |
| Brazil | 1 |
| Denmark | 1 |
| Israel | 1 |
| Czechia | 1 |
| Netherlands | 1 |
| Serbia | 1 |
| Turkey (Türkiye) | 1 |
| United Kingdom | 1 |
| Japan | 1 |
| Canada | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
- [Uzbek restaurants in the United States](https://specstream.ai/data/businesses/uzbek-restaurants/united-states)
- [Pool cleaning companies in the United States](https://specstream.ai/data/businesses/pool-cleaning-companies/united-states)
- [IP and internet law firms in the United States](https://specstream.ai/data/businesses/ip-and-internet-law-firms/united-states)
- [Ear, nose and throat clinics in the United States](https://specstream.ai/data/businesses/ear-nose-and-throat-clinics/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
